Genomics-based drug discovery offers great potential for the development of targeted therapies that can offer new and better treatment options for patients. By ...
Continue reading
Over the past year, Sano and BenevolentAI have collaborated to demonstrate how an integrated, decentralized platform — combining patient recruitment, at-home ge...
Continue reading
In this webinar, Patrick Short (Co-Founder and CEO at Sano Genetics) and Will Jones (Co-Founder and CTO at Sano Genetics) discuss the technical challenges of bi...
Continue reading
Polygenic risk scores enable clinicians and researchers to stratify patient populations by genetic risk, informing decisions on screening schedules, therapeutic...
Continue reading